Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, et al.
Therapeutic Advances in Endocrinology and Metabolism (2021) Vol. 12
Open Access | Times Cited: 23

Showing 23 citing articles:

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari, Athanasios‐Dimitrios Bakasis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3107-3107
Open Access | Times Cited: 98
Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis
A. Lopez, Janine Audrei T. Pajimna
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 21
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 81
Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease
Francesco Bellanti, Aurelio Lo Buglio, Michał Dobrakowski, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 26, pp. 3243-3257
Open Access | Times Cited: 30
Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials
Takumi Kawaguchi, Kenta Murotani, Hiromitsu Kajiyama, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 836-848
Open Access | Times Cited: 6
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms
Hager H. Shaaban, Ibrahim AlZaim, Ahmed El‐Mallah, et al.
Life Sciences (2022) Vol. 308, pp. 120956-120956
Closed Access | Times Cited: 27
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Maria Zachou, Pagona Flevari, Narjes Nasiri‐Ansari, et al.
European Journal of Clinical Pharmacology (2023) Vol. 80, Iss. 1, pp. 127-150
Open Access | Times Cited: 16
Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist
M Nakashima, Kazufumi Nakamura, Takahiro Nishihara, et al.
Nutrients (2023) Vol. 15, Iss. 3, pp. 748-748
Open Access | Times Cited: 15
Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents
Andrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, et al.
Annals of Hepatology (2023) Vol. 29, Iss. 2, pp. 101182-101182
Open Access | Times Cited: 14
Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, et al.
JGH Open (2022) Vol. 6, Iss. 7, pp. 503-511
Open Access | Times Cited: 21
Empagliflozin attenuates liver fibrosis in high‐fat diet/streptozotocin‐induced mice by modulating gut microbiota
Chuxin Huang, Jiali Qian, Ying Liu, et al.
Clinical and Experimental Pharmacology and Physiology (2024) Vol. 51, Iss. 3
Closed Access | Times Cited: 4
What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives
Carlo Alfieri, Paolo Molinari, Felice Cinque, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7728-7728
Open Access | Times Cited: 4
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
Ashot Avagimyan, Mohammad Sheibani, А. И. Трофименко, et al.
Innovative medicine of Kuban (2025) Vol. 10, Iss. 1, pp. 101-109
Open Access
Identification of key genes increasing susceptibility to atrial fibrillation in nonalcoholic fatty liver disease and the potential mechanisms: mitochondrial dysfunction and systemic inflammation
Baiyin Zhong, Zhonghui Xie, Jianhong Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors
Rosa Lombardi, Alessandro Mantovani, Annalisa Cespiati, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 4, pp. 551-558
Open Access | Times Cited: 9
The Fibrosis-5 Index Predicts Major Adverse Cardiovascular Events in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Senjiang Chen, Bouwei Zhu, Zan Luo, et al.
Angiology (2024)
Closed Access | Times Cited: 3
The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis
Man-Qiu Mo, Zichun Huang, Yuzhen Liang, et al.
Digestive and Liver Disease (2021) Vol. 54, Iss. 4, pp. 461-468
Closed Access | Times Cited: 18
A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease
Paul Manka, Eda Kaya, Ali Canbay, et al.
Digestive Diseases and Sciences (2021) Vol. 66, Iss. 11, pp. 3676-3688
Open Access | Times Cited: 16
Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis
Hirokazu Takahashi, Keiko Asakawa, Yoshinori Kosakai, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 997-1007
Open Access | Times Cited: 5
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk
Jacob A. Nysather, Eda Kaya, Paul Manka, et al.
Advances in Kidney Disease and Health (2023) Vol. 30, Iss. 4, pp. 315-335
Closed Access | Times Cited: 4
Evaluation of MASLD Fibrosis, FIB-4 and APRI Score in MASLD Combined with T2DM and MACCEs Receiving SGLT2 Inhibitors Treatment
Hua Liu, Yang-Min Hao, Sheng Jiang, et al.
International Journal of General Medicine (2024) Vol. Volume 17, pp. 2613-2625
Open Access | Times Cited: 1
Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes
Yutaro Ogawa, Takashi Nakahara, Yuwa Ando, et al.
European Journal of Gastroenterology & Hepatology (2023) Vol. 35, Iss. 9, pp. 989-996
Closed Access | Times Cited: 2
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
Husam M. Salah, Marat Fudim
Heart Failure Clinics (2022) Vol. 18, Iss. 4, pp. 625-634
Open Access | Times Cited: 2
Page 1

Scroll to top